Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      +30 YEARS' GLOBAL EXPERIENCE
      ACROSS MULTIPLE INDICATIONS1-4

       

      CHRONIC MIGRAINE

      BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

      +30 YEARS' GLOBAL EXPERIENCE ACROSS MULTIPLE INDICATIONS1-4

      CHRONIC MIGRAINE

      BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

      UK-BCM-240113. DOP: January 2025.

      The Patient Experience: Quality of Life

      Migraine is associated with a substantial personal burden, resulting from headache-related disability, a high rate of comorbidities, reduced health-related quality of life and a concomitant financial burden.6,7 Migraine can also affect work productivity, interpersonal dynamics and psychological health and wellbeing, both for the patient and for their family.8 Unsurprisingly, it has been shown that this impact is greatest in families of people with chronic migraine.8

      The personal burden of chronic migraine

      †data for patients with chronic migraine.

      The societal burden of chronic migraine

      The economic burden of the disease reflects the higher disease severity and associated comorbidities of chronic migraine compared with episodic migraine.11

      Common comorbidities in patients with chronic migraine9,14

      Table 1 QOL

      of patients with chronic migraine have comorbid depression (n=1,476)

      of patients with chronic migraine have generalised anxiety disorder (n=1,476)

      It is common for patients to experience anticipatory anxiety of their next migraine attack during a pain-free period. This can also encourage overuse of analgesic medication.12

      Chronic migraine is a complex neurological disease requiring appropriate effective management - including treatment or referrals to improve patient outcomes2,15,16

      CM: chronic migraine; COPD: chronic obstructive pulmonary disease; PTSD: post-traumatic stress disorder.

      LIVING WITH CHRONIC MIGRAINE: A PATIENT’S PERSPECTIVE

       

      References

      1. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      2. Allergan. Data on file. INT/0423/2016
      3. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      4. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/859/smpc. Accessed March 2024
      6. Buse D C, Scher A I et al. Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. Mayo Clin Proc. 2016;91(5):596-611
      7. Steiner T J, Stovner L J et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17
      8. Buse D C, Fanning K M et al. Life with migraine: effects on relationships, career, and finances from the Chronic migraine epidemiology and Outcomes (CaMEO) study. Headache. 2019;59(8):1286-1299
      9. Buse D C, Manack A et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428-432
      10. Buse D C, Rains J C et al. Sleep disorders among people with migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2019;59(1):32-45
      11. Adams A M, Serrano D et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) study methods and baseline results. Cephalalgia. 2015;35(7):563-578
      12. Agosti R. Migraine burden of disease: from the patient's experience to a socio-economic view. Headache.  2018;58 Suppl 1:17-32
      13. Bloudek L M, Stokes M et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13(5):361-378
      14. Escher C M, Paracka L et al. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2017;10(2):127-135
      15. International Headache Society (IHS). International classification of headache disorders (3rd edition) guidelines. Available at: ihs-headache.org. Accessed March 2024
      16. Weatherall M W. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6(3):115-123

       

      References

      1. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      2. Allergan. Data on file. INT/0423/2016
      3. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      4. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk /emc/product/859/smpc. Accessed March 2024
      6. Buse D C, Scher A I et al. Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. Mayo Clin Proc. 2016;91(5):596-611
      7. Steiner T J, Stovner L J et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17
      8. Buse D C, Fanning K M et al. Life with migraine: effects on relationships, career, and finances from the Chronic migraine epidemiology and Outcomes (CaMEO) study. Headache. 2019;59(8):1286-1299
      9. Buse D C, Manack A et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428-432
      10. Buse D C, Rains J C et al. Sleep disorders among people with migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2019;59(1):32-45
      11. Adams A M, Serrano D et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) study methods and baseline results. Cephalalgia. 2015;35(7):563-578
      12. Agosti R. Migraine burden of disease: from the patient's experience to a socio-economic view. Headache.  2018;58 Suppl 1:17-32
      13. Bloudek L M, Stokes M et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13(5):361-378
      14. Escher C M, Paracka L et al. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2017;10(2):127-135
      15. International Headache Society (IHS). International classification of headache disorders (3rd edition) guidelines. Available at: ihs-headache.org. Accessed March 2024
      16. Weatherall M W. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6(3):115-123

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: March 2024. UK-BCM-240043.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.